Evidence mapPaperPMID 25944874Full record

SynthesisJournal of the American Heart Association2015

Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Partha Sardar, Jacob A Udell, Saurav Chatterjee, Sameer Bansilal, Debabrata Mukherjee, Michael E Farkouh

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 6 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2019
    Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?Clinical diabetes : a publication of the American Diabetes Association · 2019
    Article
  14. Article
  15. Article
  16. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017
    Review
  17. Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles.American journal of physiology. Heart and circulatory physiology · 2017
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Partha SardarDivision of Cardiovascular Medicine, University of Utah, Salt Lake City, UT (P.S.).
Jacob A UdellCardiovascular Division, Department of Medicine, Women's College Hospital, University of Toronto, Ontario, Canada (J.A.U.) Peter Munk Centre of Excellence in Multinational Clinical Trials, University Health Network, Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Ontario, Canada (J.A.U., M.E.F.).
Saurav ChatterjeeDivision of Cardiovascular Diseases, St. Luke's-Roosevelt Hospital Center of the Mount Sinai Health System, New York, NY (S.C.).
Sameer BansilalCardiovascular Institute, The Mount Sinai Medical Center, New York, NY (S.B.).
Debabrata MukherjeeDivision of Cardiovascular Diseases, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX (D.M.).
Michael E FarkouhPeter Munk Centre of Excellence in Multinational Clinical Trials, University Health Network, Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Ontario, Canada (J.A.U., M.E.F.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegional variation in type 2 diabetes mellitus care may affect outcomes in patients treated with intensive versus standard blood glucose control. We sought to evaluate these differences between North America and the rest of the world. METHODS AND

resultsDatabases were searched from their inception through December 2013. Randomized controlled trials comparing the effects of intensive therapy with standard therapy for macro- and microvascular complications in adults with type 2 diabetes mellitus were selected. We calculated summary odds ratios (ORs) and 95% CIs with the random-effects model. The analysis included 34 967 patients from 17 randomized controlled trials (7 in North America and 10 in the rest of the world). There were no significant differences between intensive and standard therapy groups for all-cause mortality (OR 1.03, 95% CI 0.93 to 1.13) and cardiovascular mortality (OR 1.09, 95% CI 0.90 to 1.32). For trials conducted in North America, intensive therapy compared with standard glycemic control resulted in significantly higher all-cause mortality (OR 1.21, 95% CI 1.05 to 1.40) and cardiovascular mortality (OR 1.41, 95% CI 1.05 to 1.90) than trials conducted in the rest of the world (all-cause mortality OR 0.93, 95% CI 0.85 to 1.03; interaction P=0.006; cardiovascular mortality OR 0.89, 95% CI, 0.79 to 1.00; interaction P=0.007). Analysis of individual macro- and microvascular outcomes revealed no significant regional differences; however, the risk of severe hypoglycemia was significantly higher in trials of intensive therapy in North America (OR 3.52, 95% CI 3.07 to 4.03) compared with the rest of the world (OR 1.45, 95% CI 0.85 to 2.47; interaction P=0.001).

conclusionRandomization to intensive glycemic control in type 2 diabetes mellitus patients was associated with increases in all-cause mortality, cardiovascular mortality, and severe hypoglycemia in North America compared with the rest of the world. Further investigation into the pathobiology or patient variability underlying these findings is warranted.

Indexed as

Cause of DeathAdultAgedBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesFemaleHumansHypoglycemiaHypoglycemic AgentsMaleMiddle AgedNorth AmericaRandomized Controlled Trials as TopicTreatment OutcomeBlood GlucoseHypoglycemic Agentscardiovascular mortalitydiabetes mellitusintensive glycemic control

Identifiers

PMID25944874
PMCPMC4599400

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.